Resources Demo Page

UNICOM – general information

2020UNICOM Fact SheetShort introduction to UNICOM Action lines, objectivesPDF File
2020D12.2 Dissemination & Communication StrategyThis document outlines the dissemination approach geared towards adequately reflecting the large scale and broad aims of the UNICOM innovation action. for internal use only

IDMP and related standardisation(s)

2020Working Document: Gap Analysis of Existing and Need for New Standards and ProfilesWork package 1 focuses on IDMP-related standards and terminologies; its first deliverable is concerned with gaps in existing standards and profiles, and the arising need for adapted and new ones.PDF File
2020Medicinal Product, Marketing Authorization,
Pharmaceutical Product and Package Medicinal Product: Briefing Note by Jean Gonzague Fontaine (GSK)
The slides provide an overview of the relations between • MPID• PhPID• MA• PCID (and then, DCID) and explain the possible hierarchy
between these IDs.
PDF File
2020IDMP related standards and terminologies applied to pharmacovigilance:
Presentation Individual Case Safety Report. Briefing note by Anja van Haren
The slides briefly describe the expected benefits of IDMP implementation for the pharmacoviguilance domain.PDF File

IDMP-adapted submission forms and national implementations


Cross-border aspects


Presentations | Videos

2020Polypharmacy from a clinical perspective UNICOM partner Prof. Dr. R. Vander Stichele, Clinical pharmacologist at Ghent University, Belgium/ Senior Research Coordinator at I~HD, explains Polypharmacy concepts from a clinical perspective in the Horizon 2020 project C3-Cloud Webinar on 28 August 2020PDF File
2020nitial Gap Analysis on Standards Development -Presentation at HL7 International Work Group Biomedical Research & Regulation (BR&R) September 2020Those 4 slides briefly siummarize the identified gaps in WP1 for the HL7 WG audiencePDF File
2020White Paper written by nine SDOs, including CDISC, CEN, DICOM, GS1, HL7, IHE, ISO, LOINC and SNOMED International forming the Joint Initiative Council.Highlights from the JIC white paper include four standards-based initiatives that offer practical solutions to real-world problems. These initiatives include the International Patient Summary (IPS), the Identification of Medicinal Products (IDMP), COVID-19 and Genomics. The Joint Initiative Council’s SDOs work collaboratively to provide global, coordinated—not competitive—standards that address real-world healthcare issues.
PDF File
2020Presentation of UNICOM at SNOMED virtual expo-October 2020 – by Robert Stegmee and Jane MillarThe presentation describes the global problems tackled by UNICOM focusing more specifically on the relationship between IDMP and related terminologies. It explores also the role of SNOMED CT in this and informs about the ressources available to engage with the project.PDF File
2020Initial Gap Analysis on Standards Development -Presentation at HL7 International Work Group Biomedical Research & Regulation (BR&R) September 2020Those 4 slides briefly summarize the identified gaps in WP1 for the HL7 WG audiencePDF File


OpenMedicine was a Horizon 2020 funded PHC, Grant agreement No.643796. UNICOM builds on the gaps recognized in OpenMedicine. Some relevant deliverables are listed below for reference as background material.
2016D1.3 Initial openMedicine infostructureThis deliverable’s goal is to present a multi standards framework that underpins solutions to identified issues in epSOS: the EU crossborder health data exchange specifications and its pilot results. In particular the identification of medicinal products and the attention to factors related to multiple contexts are addressed creating an infostructure, based on a multi standards framework.PDF File
2016D2.3 Final identifying and descriptive attributesThis deliverable’s goal is to present the final list of identifying and descriptive attributes of medicinal products. It also gives implementation recommendations based on the materials developed in other openMedicine deliverables. D2.3 has provided relevant input to D3.2, which will extend the attribute lists to special products.PDF File
2016D3.2 Identification and description of special productsThis report extends the solution towards supporting the identification and the description of such “special” products. Furthermore, it also presents the definition of alternative and complementary use cases where the unambiguous identification of such medicinal or/and pharmaceutical products is needed.PDF File
2016D4.1 Other descriptive needs, product administration and alternative treatmentsThis document presents clusters as a tool for grouping products with the same preselected attributes. It explores the concepts behind cluster formation and useful attributes which can help in a cross-border setting for such purpose.PDF File
2016D5.2 Meeting the substitution challenge: Member State regulations and core cross-border issues – results and recommendationsThis report reviews the initial openMedicine definitions of substitution and selection of a medicinal product at the point of dispensation in a community/retail pharmacy. the revised analytical framework concerning substitution and selection issues.PDF File
2016D6.3 Recommendations and Implementation RoadmapThis document presents some of the conclusions of the openMedicine project. Two high level and ten action-oriented recommendations are formulated. All of them, except one, address issues related to the univocal identification of a medicine when dispensing in a cross-border context an electronic prescription or when displaying a Patient Summary abroad. One recommendation addresses the issue of “substitution” in the EU.PDF File